Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial

Fig. 1

Randomized Controlled Trial flow chart. 130 men diagnosed with intermediate-risk PCa treated by RP are being randomized either to LCn3 supplementation (MAG-EPA) or placebo. Intervention starts 6 weeks (acceptable range 4–10 weeks) before radical prostatectomy (RP) and ends 12 months after RP. PCa: Prostate cancer; Web-FFQ: online Food frequency questionnaire; QoL: Quality of life; PF: Psychosocial functioning; LCn3: Long chain omega-3 fatty acids; RP: Radical prostatectomy; MAG-EPA: Monoglycerides of eicosapentaenoic acid; HOSO: High oleic acid sunflower oil

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us